Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 5Other hematologic neoplasm 2Classical hematology 2

Conditions

Anemia 4Primary Myelofibrosis 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2

Interventions

Cyclophosphamide 63fludarabine phosphate 52Busulfan 48Cyclosporine 37Antilymphocyte Serum 36Peripheral Blood Stem Cell Transplantation 35Cytarabine 29Filgrastim 28Mycophenolic Acid 27Whole-Body Irradiation 26Radiotherapy 26Melphalan 26Cord Blood Stem Cell Transplantation 24Tacrolimus 23Methotrexate 23Methylprednisolone 21fludarabine 19Etoposide 16Thiotepa 11Granulocyte Colony-Stimulating Factor 11Azacitidine 10Alemtuzumab 9Daunorubicin 8sargramostim 7Idarubicin 7Decitabine 7Biopsy 7Topotecan 6Stem Cell Transplantation 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × luspatercept × Classical hematology × Clear all
NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT02631070 2021-12-17

MEDALIST

Celgene

Phase 3 Completed
229 enrolled 36 charts 1 FDA
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡